Predicted protein targets (top 19)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KDM1A | O60341 | 2/20 | 0.39 |
| ▸ | KDM1B | Q8NB78 | 1/20 | 0.39 |
| ▸ | GPR84 | Q9NQS5 | 1/20 | 0.37 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.34 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.34 |
| ▸ | HTR2A | P28223 | 9/20 | 0.33 |
| ▸ | HTR2C | P28335 | 8/20 | 0.33 |
| ▸ | HTR2B | P41595 | 6/20 | 0.33 |
| ▸ | SLC6A4 | P31645 | 1/20 | 0.33 |
| ▸ | KCNH2 | Q12809 | 1/20 | 0.33 |
| ▸ | DPP4 | P27487 | 1/20 | 0.32 |
| ▸ | MAPT | P10636 | 1/20 | 0.31 |
| ▸ | CYP1A2 | P05177 | 2/20 | 0.31 |
| ▸ | CYP3A4 | P08684 | 2/20 | 0.31 |
| ▸ | CYP2C9 | P11712 | 2/20 | 0.31 |
| ▸ | PLA2G1B | P04054 | 1/20 | 0.31 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.31 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.31 |
| ▸ | ATG4B | Q9Y4P1 | 1/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL30474348 | 1.00 | KDM1A (0.39) | KDM1AKDM1BGPR84ALDH1A1TDP1 | |
| SCHEMBL31266184 | 0.91 | GPR84 (0.37) | KDM1AKDM1BGPR84ALDH1A1TDP1 | |
| SCHEMBL693457 | 0.91 | GPR84 (0.37) | KDM1AKDM1BGPR84ALDH1A1TDP1 | |
| SCHEMBL11027502 | 0.88 | GPR84 (0.36) | KDM1AKDM1BGPR84ALDH1A1TDP1 | |
| SCHEMBL3875287 | 0.88 | GPR84 (0.38) | KDM1AKDM1BGPR84ALDH1A1TDP1 | |
| SCHEMBL488821 | 0.86 | GPR84 (0.37) | KDM1AKDM1BGPR84ALDH1A1TDP1 | |
| SCHEMBL18226969 | 0.84 | DPP4 (0.39) | DPP4 | |
| SCHEMBL14774772 | 0.83 | DPP4 (0.33) | KDM1AKDM1BGPR84DPP4MAPT | |
| SCHEMBL30030017 | 0.83 | DPP4 (0.33) | KDM1AKDM1BGPR84DPP4MAPT | |
| SCHEMBL3363763 | 0.82 | KDM1A (0.38) | KDM1AKDM1BGPR84ALDH1A1TDP1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 9 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-4605394-A1 | PYRIMIDINE SGC STIMULATORS | Tisento Therapeutics Inc. (US) | 2025-08-27 | — | — | EP | disclosed |
| US-20250223307-A1 | MDM2/MDMX DOUBLE-TARGET INHIBITOR COMPOUND, PRODRUG, PHARMACEUTICAL COMPOSITION, AND PREPARATION METHOD THEREFOR AND USE THEREOF | GLOBAL HEALTH DRUG DISCOVERY INSTITUTE (CN) | 2025-07-10 | — | — | US | disclosed |
| US-20250122171-A1 | Substituted Amine Compounds, Compositions and Methods of Use | DEEP APPLE THERAPEUTICS, INC. | 2025-04-17 | — | — | US | disclosed |
| US-20250109148-A1 | HETEROCYCLIC GLP-1 AGONISTS | SHANGHAI SHOUTI BIOTECHNOLOGY CO., LTD. (CN) | 2025-04-03 | — | — | US | disclosed |
| WO-2024104304-A1 | MDM2/MDMX DOUBLE-TARGET INHIBITOR COMPOUND, PRODRUG, PHARMACEUTICAL COMPOSITION, AND PREPARATION METHOD THEREFOR AND USE THEREOF | 北京华益健康药物研究中心 | 2024-05-23 | — | — | WO | disclosed |
| WO-2024086179-A1 | PYRIMIDINE SGC STIMULATORS | TISENTO THERAPEUTICS, INC. (US) | 2024-04-25 | — | — | WO | disclosed |
| EP-2408760-A1 | THIOPHENYL SULFONAMIDES FOR THE TREATMENT OF ALZHEIMER'S DISEASE | Bristol-Myers Squibb Company (US) | 2012-01-25 | — | — | EP | disclosed |
| US-20110071199-A1 | Thiophenyl Sulfonamides for the Treatment of Alzheimer's Disease | BRISTOL-MYERS SQUIBB COMPANY | 2011-03-24 | — | — | US | disclosed |
| WO-2010107997-A1 | THIOPHENYL SULFONAMIDES FOR THE TREATMENT OF ALZHEIMER'S DISEASE | BRISTOL-MYERS SQUIBB COMPANY (US) | 2010-09-23 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20250122171-A1 | Substituted Amine Compounds, Compositions and Methods of Use | MRGPRX2, MRGPRX1, MRGPRX4 | KDM1A 4314/4885KDM1B 2900/4885GPR84 357/4885 |
| US-20250109148-A1 | HETEROCYCLIC GLP-1 AGONISTS | GLP1R, GIPR, GCGR | KDM1A 1735/4885KDM1B 2790/4885GPR84 123/4885 |
| US-20110071199-A1 | Thiophenyl Sulfonamides for the Treatment of Alzheimer's Disease | APP, PSEN1, PSEN2 | KDM1A 2970/4885KDM1B 4093/4885GPR84 1415/4885 |
| US-20250223307-A1 | MDM2/MDMX DOUBLE-TARGET INHIBITOR COMPOUND, PRODRUG, PHARMACEUTICAL COMPOSITION, AND PREPARATION METHOD THEREFOR AND USE THEREOF | MDM2, TP53, TP53BP1 | KDM1A 2372/4885KDM1B 2687/4885GPR84 3211/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.